A recent preclinical study demonstrated the effectiveness of dual-component suppression-and-replacement (SupRep) KCNQ1 gene therapy in type 1 long QT syndrome, targeting the molecular cause of the disease [37]. Here, KCNQ1 is linked to long QT syndrome 1.